Boston Scientific buys LumenR ’ s tissue retractor

Boston Scientific (NYSE:BSX) said today that it paid an unspecified amount for a tissue retractor developed by LumenR for endoscopic resection of the gastrointestinal tract. The Newark, Calif.-based company’s device is designed to improve endoscopic sub-mucosal dissection and mucosal resection procedures to remove pre-cancerous lesions and malignant tumors in the colon, esophagus and stomach. The LumenR device also features what Boston Scientific called “enhanced visualization” of GI tract lesions. “We are excited about the potential of the LumenR system to improve visibility and control during ESD and EMR procedures and improve quality of life for patients,” endoscopy president Art Butcher said in prepared remarks. “Every year, patients around the world undergo open gastrointestinal surgery that has a profound impact on their lives. By bringing this innovative technology forward, we have an opportunity for more physicians to treat patients successfully through less invasive endoscopic procedures.” “We have seen promising outcomes in reducing both procedure times3 and patient complications4 during our evaluation of the LumenR system,” added LumenR founder & CEO Dr. Gregory Piskun. “We are excited by this investment by Boston Scientific to acquire the LumenR system and bring it to market.” Marlborough, Mass.-based Boston Scientific said it plans to integrate the LumenR system into its endoscopy dev...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Endoscopic / Arthroscopic Mergers & Acquisitions Wall Street Beat Boston Scientific LumenR Source Type: news